Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Simone Mok und 4 weiteren Autor:innen. Beteiligte Einrichtung: Irish Mycobacteria Reference Laboratory, St James's Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Innovative New Diagnostics.
Abstract (Originalsprache)
Background
WGS has the potential to detect resistance-associated mutations and guide treatment of MDR TB. However, the knowledge base to confidently interpret mutations associated with the new and repurposed drugs is sparse, and phenotypic drug susceptibility testing is required to detect resistance.
Methods
We screened 900 Mycobacterium tuberculosis complex genomes from Ireland, a low TB incidence country, for mutations in 13 candidate genes and assessed their association with phenotypic resistance to bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Results
We identified a large diversity of mutations in the candidate genes of 195 clinical isolates, with very few isolates associated with phenotypic resistance to bedaquiline (n = 4), delamanid (n = 4) and pretomanid (n = 2). We identified bedaquiline resistance among two drug-susceptible TB isolates that harboured mutations in Rv0678. Bedaquiline resistance was also identified in two MDR-TB isolates harbouring Met146Thr in Rv0678, which dated back to 2007, prior to the introduction of bedaquiline. High-level delamanid resistance was observed in two isolates with deletions in ddn, which were also resistant to pretomanid. Delamanid resistance was detected in two further isolates that harboured mutations in fbiA, but did not show cross-resistance to pretomanid. All isolates were susceptible to linezolid and clofazimine, and no mutations found were associated with resistance.
Conclusions
More studies that correlate genotypic and phenotypic drug susceptibility data are needed to increase the knowledge base of mutations associated with resistance, in particular for pretomanid. Overall, this study contributes to the development of future mutation catalogues for M. tuberculosis complex isolates
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Irish Mycobacteria Reference Laboratory, St James's Hospital, Dublin, Ireland.
- Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, the University of Dublin, St James's Hospital Campus, Dublin, Ireland.
ORCID-Profile: Simone Mok
Förderung
- Foundation for Innovative New Diagnostics
Zitieren
APA
Mok, S., Roycroft, E., Flanagan, P. R., Wagener, J., & Fitzgibbon, M. M. (2023). Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad252
Vancouver
Mok S, Roycroft E, Flanagan PR, Wagener J, Fitzgibbon MM. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad252
BibTeX
@article{Mok2023,
author = {Mok, Simone and Roycroft, Emma and Flanagan, Peter R and Wagener, Johannes and Fitzgibbon, Margaret M},
title = {Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad252}
}
EUVIMED